Last updated: March 12, 2026
What Is the Scope of Patent ME01239?
Patent ME01239 covers a pharmaceutical invention registered in Montenegro. Its scope defines the legal protection conferred by the patent, primarily involving specific formulations, compounds, or indications. The patent was filed to protect a unique chemical entity or therapeutic method.
Based on standard patent documentation, the scope is limited to:
- A particular chemical compound or a class of compounds.
- Methods of manufacturing the compound.
- Specific therapeutic uses or indications.
- Formulation specifics, such as dosage forms or delivery mechanisms.
In the absence of the full patent text, typical scope parameters include:
| Aspect |
Details |
| Patent type |
Drug composition patent or method patent |
| Likely protected elements |
Chemical structure, synthesis process, therapeutic use |
| Duration |
20 years from the filing date |
| Geographical scope |
Montenegro only, unless international (PCT) or regional filings |
What Do the Claims Cover?
The claims define the exclusive rights of the patent owner. For ME01239, the claims likely include:
-
Compound Claims: Specific chemical compounds or derivatives, for example, a novel molecule with specified structural features. These claims are usually the broadest and most critical for patent scope.
-
Method Claims: Processes for synthesizing the compound or specific methods of using the drug to treat particular conditions.
-
Formulation Claims: Specific pharmaceutical forms like tablets, capsules, or injectable solutions containing the compound.
-
Use Claims: Routine patent practice includes claims to the use of the compound for treating particular diseases or conditions, e.g., cancer, inflammation, or infectious diseases.
These claims typically have hierarchical scope, with broad claims covering compounds, and narrower claims covering specific formulations or therapeutic uses.
Patent Landscape in Montenegro for Pharmaceutical Drugs
Montenegro’s patent framework aligns with the European Patent Convention (EPC). It is a member of the European Patent Organisation but not a party to the European Patent Convention itself. National patent law is regulated under the Law on Inventions, Patents, and Other Industrial Property Rights.
Key points for the pharmaceutical patent landscape:
-
Patent Term: 20 years from application filing, similar to European and international standards.
-
Patentability Criteria: Patentable inventions include new chemical compounds, processes, and compositions, provided they meet novelty, inventive step, and industrial applicability.
-
Drug Patenting Trends: Montenegro has a limited but growing pharmaceutical innovation sector. Patent applications tend to follow European standards, with a preference for chemical and biological innovations.
-
Patent Filing Pathways: Pharmaceutical inventors often file national applications directly or pursue PCT applications designating Montenegro to extend protection.
Important considerations:
-
Montenegro's patent law allows for patent term extensions only in cases of regulatory delays, but these are rarely granted in pharmaceutical patents.
-
Post-grant opposition procedures are possible within a 6-month window after patent grant.
-
Licensing and technology transfer arrangements are common for pharmaceutical patents, given the relatively small domestic market.
Comparative Analysis with Regional and International Patent Laws
| Aspect |
Montenegro (ME01239) |
European Patent Convention (EPC) |
International (PCT) Applications |
| Filing Requirement |
National or PCT |
EPC (regional) |
PCT System |
| Patent Term |
20 years |
20 years |
20 years |
| Claims Scope |
Based on application |
Broad, including chemical, biological, use claims |
Broad, dependent on jurisdictions |
| Data Exclusivity |
Not explicitly defined |
Varies, typically 5-10 years |
Usually 5 years for pharmaceuticals |
| Opposition Period |
6 months post-issuance |
9 months from publication |
Varies per jurisdiction |
Key Takeaways
-
Patent ME01239 likely protects a specific chemical entity, its synthesis, and uses, with a focus on pharmaceutical applications.
-
The patent claims probably include composition, synthesis process, and therapeutic use, with hierarchical scope from broad to narrow claims.
-
Montenegro’s patent law ensures a 20-year protection window, similar to European standards; however, enforcement and litigation capacity remains limited.
-
Filing strategies should include PCT applications to secure broader regional protection, given Montenegro’s limited domestic market.
-
Patent landscape analysis indicates a focus on chemical innovation with a regional alignment toward European standards.
FAQs
1. Can I challenge the validity of Montenegro patent ME01239?
Yes, opposition procedures exist within six months of patent grant. Grounds include lack of novelty, inventive step, or industrial applicability.
2. Does Montenegro recognize data exclusivity for pharmaceutical patents?
Montenegro does not explicitly provide data exclusivity separate from patent rights. Data protection policies align with European standards but are limited.
3. What are the main pathways for patent protection in Montenegro?
Applicants can file directly for national protection or pursue international filings through the PCT system, designating Montenegro for subsequent regional filings.
4. How enforceable are pharmaceutical patents in Montenegro?
Enforcement can be challenging due to limited specialized enforcement infrastructure, but patent holders can initiate legal proceedings to stop infringing activities.
5. Are supplementary protection certificates (SPCs) available?
Montenegro does not currently offer SPCs; patent term extension options are limited to specific cases like regulatory delays, which are rare.
References
[1] Montenegrin Law on Inventions, Patents, and Other Industrial Property Rights. (2021). Government of Montenegro.
[2] European Patent Convention. (1973). European Patent Office.
[3] World Intellectual Property Organization. (2022). Patent Information Data.
[4] European Patent Office. (2022). Patent law harmonization and practice.
